166 related articles for article (PubMed ID: 16956348)
1. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
[No Abstract] [Full Text] [Related]
2. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
[No Abstract] [Full Text] [Related]
3. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
[No Abstract] [Full Text] [Related]
5. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
6. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
[No Abstract] [Full Text] [Related]
8. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
9. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
[No Abstract] [Full Text] [Related]
10. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
McLornan D; Percy M; McMullin MF
Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
[No Abstract] [Full Text] [Related]
12. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
[TBL] [Abstract][Full Text] [Related]
13. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
McClure R; Mai M; Lasho T
Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
[No Abstract] [Full Text] [Related]
14. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
15. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
16. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
17. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
[No Abstract] [Full Text] [Related]
18. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
19. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho TL; Mesa R; Gilliland DG; Tefferi A
Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
[No Abstract] [Full Text] [Related]
20. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
